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Clinical Infectious Diseases
VIEWPOINTS ARTICLE

Molecular Testing for Acute Respiratory Tract Infections:
Clinical and Diagnostic Recommendations From the
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The clinical signs and symptoms of acute respiratory tract infections (RTIs) are not pathogen specific. Highly sensitive and specific
nucleic acid amplification tests have become the diagnostic reference standard for viruses, and translation of bacterial assays from
basic research to routine clinical practice represents an exciting advance in respiratory medicine. Most recently, molecular diagnostics have played an essential role in the global health response to the novel coronavirus pandemic. How best to use newer molecular
tests for RTI in combination with clinical judgment and traditional methods can be bewildering given the plethora of available assays
and rapidly evolving technologies. Here, we summarize the current state of the art with respect to the diagnosis of viral and bacterial
RTIs, provide a practical framework for diagnostic decision making using selected patient-centered vignettes, and make recommendations for future studies to advance the field.
Keywords. respiratory viruses; molecular diagnostics; utilization.
The number of Food and Drug Administration (FDA)–
cleared molecular diagnostics for acute respiratory tract infection (RTI) has increased significantly over the last decade
(Table 1). In addition, the FDA has granted Emergency Use
Authorization for a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid amplification tests (NAATs) [1]. Highly sensitive and specific NAATs
capable of detecting 1 or more viruses have become the diagnostic “gold standard” in clinical virology. In addition, several of the newest assays also detect and identify the most
common causes of bacterial pneumonia along with selected
drug-resistance determinants. Clinicians and microbiology
laboratories now have multiple testing options that generate results within minutes to hours. Deciding which assay
or combination of assays to choose, and when to use them,
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depends on a variety of factors including the clinical setting,
institutional resources, workflow, and cost.
Recent studies have examined the potential impact of respiratory NAAT on clinical outcomes and resource utilization. Most publications have focused on viral testing, with
the majority evaluating influenza testing only. Rapid molecular testing for influenza has the potential to reduce unnecessary antibiotic use [2–4], improve antiviral prescribing [2,
5–7], limit additional ancillary testing [3, 8], shorten hospital or emergency department (ED) lengths of stay [2–4, 8,
9], and optimize infection-control practices [7]. Molecular
testing for multiple respiratory viruses simultaneously may
also be more cost-effective than traditional antigen- or
culture-based methods from a laboratory perspective, especially given certain thresholds of disease prevalence [10, 11].
However, not all molecular studies have reported demonstrable improvements in outcomes or cost savings [12–14].
This lack of clarity stems from the heterogeneity and variable
quality of published studies. Small sample sizes and comparisons to historical controls are common weaknesses of the respiratory diagnostic literature. Furthermore, complexities in
results interpretation combined with variable infrastructure
to provide results in a timely manner are real-life challenges.
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Table 1.

Landscape of Food and Drug Administration–Cleared Diagnostic Tests for Acute Respiratory Tract Infection
Approved Specimen Types

Timeb

Costc

Influenza A/B only

NS direct, NPS direct, NP, NPS

15–30 minutes

$$–$$$

RSV only

NPS direct, NS, NPS

15 minutes

$$$

Flu A/B plus RSV

NS, NPS

20–30 minutes

$$–$$$

Multiple viruses plus atypical bacteria

NPS

60 minutes

$$$$

Influenza A/B only

NS, NPS

0.5–2 hours

$$

PIV only

NPS

3.5 hours

$$

Flu A/B plus RSV

NS, NPS, NPA, NW

0.5–3.5 hours

$$–$$$$

RSV plus hMPV

NS, NPS

0.75 hours

$S

AdV, hMPV plus RV

NPS

3.5 hours

$$

Multiple viruses plus atypical bacteria

NPS

0.75–5 hours

$$$$

Multiple bacteria with resistance

ETA

4–5 hours

$$$$$

Multiple viruses and bacteria with resistance

S, ETA, BAL

60 hours

$$$$$

Targetsa
CLIA-waived assays

Moderate- to high-complexity assays

The FDA’s website contains a comprehensive list of cleared molecular microbial tests: https://www.fda.gov/medical-devices/vitro-diagnostics/nucleic-acid-based-tests. Definitions: Assays
vary in the type of specimens approved by the FDA and in the number of organisms they can detect: “Direct” testing uses a swab, without transport media; “Atypical” bacteria may include
Bordetella pertussis, Bordetella parapertussis Chlamydia pneumoniae and/or Mycoplasma pneumoniae; “Multiple viruses” may include AdV, coronaviruses, hMPV, influenza A/B, PIV, RSV,
and RV; “Multiple bacteria” may include Acinetobacter calcoaceticus-baumannii complex, Citrobacter freundii, Enterobacter cloacae complex, Escherichia coli, Haemophilus influenzae,
Klebsiella pneumoniae group, K. oxytoca group, K. variicola group, Legionella pneumophila, Moraxella catarrhalis, Morganella morganii, Proteus species, Pseudomonas aeruginosa, Serratia
marcescens, Staphylococcus aureus, Stenotrophomonas maltophilia, Streptococcus agalactiae, S. pneumoniae, and S. pyogenes; antimicrobial “resistance” genes may include tem,
mecA/C, MREJ, CTX-M, KPC, NDM, Oxa-48-like, Oxa-23, Oxa-24, Oxa-58, IMP, and VIM.
Abbreviations: AdV, adenoviruses; BAL, bronchoalveolar lavage; CLIA, Clinical Laboratory Improvement Amendments; ETA, endotracheal aspirate; FDA, Food and Drug Administration;
hMPV, human metapneumovirus; NPA, nasopharyngeal aspirate; NPS, nasopharyngeal swab; NS, nasal swab; NW, nasal wash; PIV, parainfluenza viruses; RSV, respiratory syncytial virus;
RV, rhinovirus; S, induced/expectorated sputum.
a
The FDA categorizes diagnostic tests by their complexity. Nonlaboratory staff can perform waived tests because they are deemed simple to use and the FDA has determined there is little
chance the test will provide wrong information or cause harm if done incorrectly. Moderate- to high-complexity tests must be performed in qualified laboratories or sites that meet certain
regulatory requirements and quality standards.
b
Assay run time is displayed in minutes or hours. It is important to differentiate run time from total turnaround time to results, which includes the time from specimen collection to issuance
of results by the laboratory.
c
Approximate cost (US dollars) is derived from the quoted list price for reagents plus controls per test reaction. Instrument costs, depreciation, and labor are not included. $ = 1–25,
$$ = 26–50, $$$ = 51–100, $$$$ = 101–150, $$$$$ =151–200.

On-the-ground effectiveness may depend as much on the logistics of testing and response to results as it does on the
intrinsic accuracy of the NAATs themselves. A conceptual
model of the critical components of diagnostic test efficacy
is depicted in Figure 1.
The Diagnostics Committee of the Infectious Diseases
Society of America (IDSA) conducted a comprehensive review of the respiratory molecular diagnostic literature. The
aims of the project were as follows: (1) to categorize clinical situations for which the available body of evidence supports viral and/or bacterial testing, (2) to highlight nuances
in results interpretation that impact patient management
and antimicrobial stewardship (AS), and (3) to identify critical knowledge gaps to guide future research. Queries of
MEDLINE, Embase, and the Cochrane Library, with an emphasis on peer-reviewed manuscripts published in the last
5 years (2015–2019), identified recent outcome and cost-effectiveness studies. An update was performed in March 2020
to focus specifically on the growing SARS-CoV-2 literature.
Through a standardized assessment of individual articles,
we formulated key clinical questions pertaining to the rational use of current FDA-cleared molecular tests. Practical
issues and unmet diagnostic needs are discussed in the context of 2 patient vignettes (Boxes 1 and 2).
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QUESTION 1: TO TEST OR NOT TO TEST? THAT IS THE
FIRST QUESTION

The first question to consider when deciding whether to test
a patient with suspected RTI is “how will the results affect my
clinical management?” The answer to this question depends on
a variety of factors, including the patient’s severity of illness,
duration of symptoms, comorbidities, net state of immunosuppression, availability of other ancillary test results at time of
presentation, and anticipated turnaround time to results. In addition, disease prevalence (ie, the pretest probability of a given
pathogen) is integral to diagnostic decision making since it affects the positive- and negative-predictive values of these assays.
Testing for Viral Pathogens

In the first vignette (Box 1), which predates the novel coronavirus pandemic, an otherwise healthy child presenting with an
upper respiratory infection during a period of low influenza
activity does not necessarily need influenza-specific testing.
Figure 2 illustrates the impact of influenza prevalence on the
predictive value of NAAT. During periods of low prevalence,
positive results have a high likelihood of being falsely positive.
Furthermore, since this patient has no strong indication for antiinfluenza therapy [16], influenza-specific testing is unlikely to
affect the decision to prescribe antiviral therapy. Alternatively, if

Technical Efficacy ↔ Diagnos c Accuracy Efficacy
Resource
requirements

Time to result

Sensi vity and
specificity

Posi ve and nega ve
predic ve value

Diagnos c Decision Efficacy
Helpful in making diagnosis

Changes probabili es in differen al diagnosis

Therapeu c Efficacy
Therapy change aer tes ng

Procedure change aer tes ng

Pa ent Outcome Efficacy
Pa ents improved with test
compared to without

Morbidity and procedures
avoided with tes ng

Quality-adjusted life years
impact

Societal Efficacy
Cost-benefit or cost-effec veness impact from societal perspec ve

Figure 1.

Conceptual hierarchical model of efficacy for molecular diagnostics. Adapted with permission from Fryback and Thornbury [15].

BOX 1. PEDIATRIC VIGNETTE

BOX 2. ADULT VIGNETTE

A 4-year-old fully immunized girl with no significant past
medical history presents to her pediatrician’s office in July
of 2019 with cough, runny nose, and fever of 3 days’ duration. Several other preschool classmates are ill with similar
symptoms. The patient has a fever but other vital signs are
normal. She is breathing comfortably without signs of respiratory distress. On examination, lungs sounds are coarse
with good air movement and there are no other focal findings. No respiratory testing is ordered. Instead, the patient
and her family are reassured.

A 47-year-old male liver transplant recipient is admitted
to the intensive care unit in December of 2019 with fever,
respiratory distress, and new bilateral infiltrates. Empiric
vancomycin, cefepime, and oseltamivir are initiated and
the next day bronchoscopy is performed. Gram stain of
bronchoalveolar lavage (BAL) fluid shows ≥2 gram-positive cocci with many polymorphonuclear cells. A rapid
multiplex polymerase chain reaction (PCR) panel targeting
viruses and bacteria detects mecA positive Staphylococcus
aureus (107 genome copies/mL) and Haemophilus influenza
(104 genome copies/mL). BAL cultures remain negative.

the patient were significantly immunocompromised, had a severe influenza-like illness, or if the detection of another respiratory virus would influence the decision to prescribe an antiviral
or withhold antibiotics, then syndromic testing for multiple viruses would be indicated.
The IDSA and Centers for Disease Control and Prevention
(CDC) have published influenza testing algorithms for adults

and children [16–18]. Although relatively few studies have assessed the cost-effectiveness of molecular testing, modeling suggests that an approach of testing and then treating is generally
preferred to empiric anti-influenza treatment during periods of
moderate disease prevalence or when risk for severe disease is
moderate to high [19, 20]. To be most useful in the outpatient
VIEWPOINTS • cid 2020:XX (XX XXXX) • 3

setting, influenza results should be available during the patient
visit. In the ED, the greatest impact is observed when results are
issued in under 2 hours [21, 22].
Best practices for the diagnosis of coronavirus disease 2019
(COVID-19) are rapidly evolving. In the setting of ongoing
community transmission, testing all symptomatic individuals
is optimal for informing isolation practices, contact tracing,
and evaluating the changing epidemiology. However, collection device and nucleic acid extraction reagent shortages have
affected the availability of testing in some areas of the United
States. In response, the IDSA [23] and others have developed
expert recommendations for prioritized testing when resources
are limited.
Similar guidance for other non–influenza viruses exists
only in selected immunocompromised host guidelines [24–
27], where initial testing for multiple viruses in addition to
influenza is endorsed, and in the American Academy of
Pediatrics recommendation against routine viral testing for
children with bronchiolitis [28]. In a general adult population,
non–influenza virus detections may not have the same influence on antibiotic prescribing and/or lengths of stay as do influenza results [2, 3, 29, 30]. Limited sample sizes, however,
preclude drawing firm conclusions here and few studies have
specifically assessed impact on the management of immunocompromised hosts [31]. Future studies need to be powered to
measure the clinical impact of non–influenza virus detections,
especially for those being evaluated in the ED or on admission
to the hospital.
Testing for Bacterial Pathogens

Until recently, commercially available NAATs were limited to viral pathogens plus a few “atypical” bacteria including Mycoplasma pneumoniae, Chlamydia pneumoniae,
and Bordetella species. It is clear that the presence of new or
worsening infiltrates on chest X-ray is an independent predictor

of antibiotic use irrespective of respiratory virus detection [29].
Thus, confidently excluding bacterial coinfection in patients
with a suspected viral infection may help reduce unnecessary
antibiotic use. In addition, rapid tests that accurately rule in
or out additional bacterial pathogens such as Pseudomonas,
methicillin-resistant Staphylococcus aureus (MRSA), Legionella,
or multidrug-resistant gram-negative organisms should have
value for initial management decisions as long as they can reliably discriminate between infection and respiratory tract
colonization.
Current community-acquired pneumonia (CAP) [32] and
hospital- or ventilator-associated pneumonia (HAP and VAP)
guidelines [33] do not address molecular testing for bacterial pathogens other than a recommendation for nasal MRSA
screening in patients with HAP/VAP. Since multiplex bacterial
pneumonia panels are so new, their test performance and potential impact on clinical decision making are not yet established.
In the absence of high-quality data, bacterial NAAT may prove
most useful in situations where patients have new or worsening
lung infiltrates, are moderately to severely ill, have received
empiric antibiotics before obtaining cultures, and/or there is
concern for multidrug-resistant bacteria or a polymicrobial infection. A recent meeting abstract highlights the importance of
combined viral and bacterial testing, where clinician-directed
testing would have missed potentially important viruses [34].
The second vignette (Box 2) is an example of the type of patient most likely to benefit from broad syndromic testing for
viruses and bacteria at the same time. Molecular detection of
high quantities of MRSA supports continuation of vancomycin
in this case despite negative culture results. In addition, negative influenza results combined with detection of Haemophilus
influenzae allow consideration of more-targeted gram-negative
coverage along with cessation of antiviral therapy. Uncertainties
associated with the interpretation of bacterial NAAT from lower
respiratory tract (LRT) are discussed further under Question 3.

Figure 2. The importance of pretest probability. The predictive value of rapid molecular testing is displayed over the course of a typical influenza season given the published sensitivity and specificity of current influenza molecular assays. Abbreviations: ILI, influenza-like illness; NPV, negative-predictive value; PPV, positive-predictive value.
4 • cid 2020:XX (XX XXXX) • VIEWPOINTS

QUESTION 2: IF I DECIDE TO TEST, WHICH
APPROACH IS BEST?
Testing for Influenza

Simple sample-to-answer molecular platforms and point-ofcare devices enable high-performance influenza testing with a
rapid turnaround time. In a recent meta-analysis, the pooled
sensitivity and specificity of rapid viral NAAT were 90.9% and
96.1%, respectively [35]. The CDC and IDSA influenza guidelines both favor molecular detection of influenza, as opposed
to antigen testing, in the outpatient and hospital setting [16–
18]. Whether molecular influenza testing for all patients is the
most cost-effective approach remains uncertain. For example,
initial testing with a less expensive digital influenza immunoassay followed by molecular confirmation of negative results for
high-risk or hospitalized patients is an alternative strategy that
warrants additional study.
Testing for SARS-CoV-2

The World Health Organization declared a public health emergency of international concern on 30 January 2020. Shortly
thereafter, the US Secretary of Health and Human Services
announced that circumstances existed justifying authorization of the emergency use of SARS-CoV-2 diagnostics. More
than 2 dozen different NAATs have received Emergency Use
Authorization from the FDA [1]. Known concentrations of inactivated virus were used to determine the analytical characteristics of these tests. In contrast, clinical test performance (ie,
sensitivity and specificity) has yet to established.
Available evidence suggests that SARS-CoV-2 is detectable in
nasopharyngeal (NP) and oropharyngeal (OP) specimens, with
peak levels typically measurable during the first week of symptoms [36–38]. The NP samples may be more sensitive than OP
samples [36, 39], but detection rates appear to vary from patient
to patient and change over the course of illness [37, 39]. Some
patients with pneumonia, for example, have negative NP/OP
samples but positive lower airway samples [40, 41]. Like other
viral diseases, shedding of viral RNA in respiratory secretions
may persist beyond resolution of symptoms and seroconversion
[37]. Whether these patients remain infectious to others is uncertain. Much work remains to define the optimal approach to
COVID-19 diagnosis, and comparisons across assays and specimen types are important unmet needs.
Testing for a Broad Range of Respiratory Pathogens Simultaneously

Upfront multiplex testing for multiple viruses may be most
cost-effective in pediatric patients, where it can reduce unnecessary antibiotics as well as chest radiographs [42]. In contrast,
a Veterans Affairs study evaluating a multiplex NAAT assay
in adult outpatients during influenza season suggested that
testing for influenza alone may be more cost-effective than a
syndromic approach in this patient population [30]. Multiplex
viral NAAT (potentially combined with bacterial NAAT) also

makes clinical sense for immunocompromised and critically ill
patients with pneumonia as well as for those with exacerbations
of airway disease [43]. These are situations where treatment of
non–influenza viruses such as respiratory syncytial virus (RSV)
or adenovirus may be considered (eg, in a stem-cell-transplant
patient) and rapid test results are most likely to influence subsequent modifications of empiric broad-spectrum antibiotics.
While the analytic sensitivity of multiplex NAAT decreases
the likelihood that an important pathogen will be missed, enhanced detection also complicates interpretation. Prolonged
virus shedding detectable by NAAT, but not culture, is described in immunocompromised individuals [44], and children often asymptomatically shed respiratory viruses [45]. In
addition, nonviable bacteria may be detected by NAAT. These
phenomena have important implications for hospital infection
control and treatment decisions. Co-detection of multiple bacteria, viruses, or bacteria plus viruses is also common using
NAAT, occurring in up to 30–40% of cases [46, 47]. Available
studies on the medical significance of mixed infections have reported variable results. Additional studies are needed to understand whether coinfections portend poorer prognosis.
High analytic sensitivity also translates to high negativepredictive values (ie, generally >97%, depending on prevalence),
but there may be important differences among individual panel
targets or across manufacturers. It is incumbent on clinicians
and laboratorians to understand the test characteristics of each
individual panel target, especially if the results inform antibiotic
de-escalation in high-acuity settings. Even the largest multiplex
panels do not detect all potential pathogens, and the optimal
multiplex panel design remains a matter of debate. As a result,
current tests are not yet a replacement for bacterial and fungal
culture with antimicrobial susceptibility testing. Culture also
remains essential for epidemiologic studies, vaccine-related decisions, and local antibiograms.
Current bacterial pneumonia panels are intended for use
with LRT samples, but FDA approval for specific specimen
types (eg, sputum, endotracheal, and/or bronchial) varies
by assay. Studies comparing diagnostic yield using different
sample types collected concurrently from the same patient are
currently underway. This sort of comparison will be useful for
assessing the overall predictive value of test results. Factors to
consider here include the higher likelihood of sputum samples
to contain upper airway commensals and the theoretic benefit
of site-directed bronchoalveolar lavage (BAL) over blind endotracheal suctioning in mechanically ventilated patients. In addition, negative upper respiratory tract (URT) testing for viruses
and atypical bacteria is not sufficient to rule out LRT infection.
In severe influenza, for example, viral shedding lasts a median
of 6 days in URT as compared with a median of 11 days in LRT
specimens [48] and certain strains of influenza including H1N1
and H5N1 preferentially or exclusively infect the LRT [49, 50].
A study of immunocompromised adults with RSV also observed
VIEWPOINTS • cid 2020:XX (XX XXXX) • 5

significantly better sensitivity with LRT versus URT specimens
[51]. Consequently, LRT sampling after negative URT testing is
advisable when there is strong clinical suspicion for influenza or
RSV and is recommended for immunocompromised patients
with lung infiltrates.
QUESTION 3: HOW DO I INTERPRET THE
SIGNIFICANCE OF BACTERIAL DNA DETECTIONS IN
THE LOWER RESPIRATORY TRACT?

Molecular diagnostics generally detect more bacterial pathogens than culture [12, 46, 47, 52, 53]. This likely reflects the
inherent sensitivity of NAAT combined with potential detection of dead, fastidious, colonizing, or metabolically impaired
organisms. Assessing previous receipt of antibiotics at the
time of specimen collection will be critical for interpreting
NAAT-positive/culture-negative results. It is also important to
remember that neither culture nor NAAT separates airway colonizers from invasive pathogens. However, use of quantitative
methods may improve the clinical specificity of culture for VAP
[33, 54], with higher values being more predictive of true infection. One of the FDA-cleared multiplex pneumonia panels does
report relative organism abundance for 15 of its bacterial targets [55]. Bacterial detections are grouped into semiquantitative
bins of 104, 105, 106 and more than 107 genomic copies/mL,
which are calculated relative to calibrator material in the assay.
Values below 103.5 copies/mL are reported as “not detected.” In
general, there is moderate correlation between genomic units
and culture quantitation, with genome copies/mL tending to
be higher than the corresponding colony forming units/mL
measurements.
In the second vignette (Box 2), the patient’s BAL contained
much higher concentrations of MRSA nucleic acid than
H. influenzae. It is possible that the low-level H. influenzae detection simply represents airway colonization and the negative
culture is a result of previous antibiotics. However, in a critically ill immunocompromised patient, the consequences of not
treating a potential pathogen likely outweigh the risk of toxicity from targeted antimicrobial therapy. Whether detection
of high versus low concentrations of potential pathogens has
prognostic value deserves additional study and this will vary
Table 2.

by organism. A small single-center study did observe increased
lengths of intensive care unit stay and more discharge diagnosis
codes for pneumonia in patients with higher NAAT genomic
copies/mL, which suggests that binning may have clinical value
and potentially help clinicians distinguish true infections from
colonization [56].
QUESTION 4: DOES PARTNERSHIP WITH ANTIBIOTIC
STEWARDSHIP ENHANCE THE IMPACT OF
RESPIRATORY DIAGNOSTIC TESTING?

Antimicrobial stewardship guidelines advocate rapid testing for
broad panels of respiratory viruses as an important intervention
to reduce the use of inappropriate antibiotics [57]. Nevertheless,
there have yet to be any interventional studies assessing the
safety and efficacy of antimicrobial de-escalation based on multiplex NAAT results. Active AS studies have mostly used preversus postintervention designs and have focused primarily
on viral testing. The highest rates of antibiotic discontinuation
(51%) with prospective audit and feedback were observed when
a virus is detected, bacterial cultures are negative, and chest imaging is normal [58]. Otherwise, only modest antibiotic discontinuation rates (14–24% of cases) with active AS in the setting
of viral RTIs were accomplished [59–61]. This is likely due to
the inability to exclude bacterial coinfection with confidence
in a meaningful time frame. The combination of respiratory
virus NAAT with a serum biomarker (eg, procalcitonin) or host
immune-response profile suggestive of a viral, but not bacterial,
infection may be useful in this regard [62, 63].
The fact that molecular testing of respiratory specimens for
bacteria detects more organisms than traditional culture has led
to concerns that multiplex NAAT may paradoxically increase
antimicrobial use. Moreover, early experience suggests that
genotypic resistance aligns relatively poorly with phenotypic
susceptibility results [52, 53, 64]. Molecular methods detect
only the most common resistance determinants and resistance
genes present in “off panel” organisms will complicate interpretation. Guidance from an AS team will likely be required to
derive maximal benefit from LRT respiratory NAAT, just as it
has for bloodstream infections [65]. Whether combined use of
biomarkers or host immune-response plus molecular pathogen

Committee Recommendations for Future Respiratory Diagnostic Studies

Development of New and Innovative Diagnostics

Cost-effectiveness Studies of Available Tests

Definition of Optimal Testing Algorithms and AS Interventions

Novel biomarker discovery and host-response signa- Prospective studies that capture both clinical out- Studies combining host-response signatures or biotures that help separate viral, bacterial, fungal, and comes and costs.
markers with pathogen detection and active AS.
coinfections from colonization or no infection.
Continued refinement and analytical evaluation of
unbiased next-generation sequencing platforms
for use in clinical settings.
Targeted tests for fungi, nontuberculous mycobacteria, and Nocardia.

Specific assessments of the impact of non–influ- Prospective studies of AS interventions in conjunction
enza virus detections, mixed infections, and
with NAAT results and testing algorithms in the outbacterial pneumonia panels with antibioticpatient clinic, intensive care unit, and immunocomresistance markers.
promised host settings.

Abbreviations: AS, antimicrobial stewardship; NAAT, nucleic acid amplification test.
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testing and AS monitoring can promote safe reductions in antibiotic use requires additional exploration. Targeting interventions to lower-risk patients with a virus detection, where
prescribers may be more adherent to recommendations, may be
the most pragmatic place to start.
CONCLUSIONS AND CLINICAL RECOMMENDATIONS

Molecular diagnostics have revolutionized the detection of respiratory viruses. Compared with classical culture- and antigenbased methods, these tests have high sensitivity and there is
potential for a clinically meaningful turnaround time to actionable results that may reduce diagnostic uncertainty and help
guide early management decisions. Newer molecular assays
now target SARS-CoV-2 as well as common causes of bacterial pneumonia. Whether SARS-CoV-2 will become a seasonal
virus is unknown, but we are likely to see this virus included as
a part of syndromic respiratory diagnostic panels in the future.
In general, respiratory NAAT is most useful in the setting
of intermediate pretest probability and intermediate disease
severity. This is a situation where a negative test may permit
withholding of initial empiric coverage of a potential pathogen, whereas a positive test can allow therapy to be focused
against a particular pathogen, thus increasing therapeutic efficacy, decreasing avoidable drug toxicity, and potentially reducing unnecessary additional testing. Under conditions of
high pretest probability and/or high risk of an adverse outcome, these tests generally lack sufficient sensitivity for a clinician not to empirically “cover” a potentially life-threatening
pathogen. When there is a low pretest probability for a particular pathogen and/or low risk of adverse clinical outcomes,
available tests may not add sufficient clinical value to constitute an efficient use of limited medical resources. Decisions
regarding deployment of molecular diagnostics at the level of
the hospital laboratory, and for a hospital system as a whole,
should also consider their value in guiding protocols and
policy—for example, in hospital epidemiology and antibiotic
stewardship. Policies for effective use must be evaluated in an
ongoing fashion as technology evolves and evidence in support of best practice emerges.
UNMET DIAGNOSTIC NEEDS AND FUTURE
DIRECTIONS

Rapid molecular diagnostics are powerful tools for the evaluation and management of patients with suspected RTI. However,
optimal testing algorithms and the potential impact that these
tests have on patient management decisions and outcomes require further study in a variety of clinical settings. Table 2 summarizes the investigations that we believe are required to address
the most important knowledge gaps and unmet diagnostic
needs for RTIs. Well-designed research is especially needed in
the areas of novel assay development, cost-effectiveness, and test

utilization combined with AS. Outcome studies should ideally
be prospective and include large enough numbers of patients
to make statistically meaningful comparisons. Last, funding for
interventional trials of respiratory diagnostics is a priority.
Notes
Disclaimer. The contents of this document are the authors’ opinions and
do not necessarily reflect those of the Department of Veterans Affairs or the
US government.
Potential conflicts of interest. A. M. C. is an employee of the Department
of Veterans Affairs. R. B. reports grants from the National Institutes of
Health. R. B. reports grants from bioMérieux, Biofire, and Roche, outside
the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts
of Interest. Conflicts that the editors consider relevant to the content of the
manuscript have been disclosed.
References
1. US Food and Drug Administration. Coronavirus disease 2019 (COVID-19)
emergency use authorizations in vitro diagnostics. Available at: https://www.
fda.gov/medical-devices/emergency-situations-medical-devices/emergency-useauthorizations#covid19ivd. Accessed 31 March 2020.
2. Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care
testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial.
Lancet Respir Med 2017; 5:401–11.
3. Rappo U, Schuetz AN, Jenkins SG, et al. Impact of early detection of respiratory
viruses by multiplex PCR assay on clinical outcomes in adult patients. J Clin
Microbiol 2016; 54:2096–103.
4. Rogers BB, Shankar P, Jerris RC, et al. Impact of a rapid respiratory panel test on
patient outcomes. Arch Pathol Lab Med 2015; 139:636–41.
5. Andrews D, Chetty Y, Cooper BS, et al. Multiplex PCR point of care testing versus
routine, laboratory-based testing in the treatment of adults with respiratory tract
infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use. BMC Infect Dis 2017; 17:671.
6. Chu HY, Englund JA, Huang D, et al. Impact of rapid influenza PCR testing on hospitalization and antiviral use: a retrospective cohort study. J Med Virol 2015; 87:2021–6.
7. van Rijn AL, Nijhuis RHT, Bekker V, et al. Clinical implications of rapid ePlex(R)
respiratory pathogen panel testing compared to laboratory-developed real-time
PCR. Eur J Clin Microbiol Infect Dis 2018; 37:571–7.
8. Wabe N, Li L, Lindeman R, et al. Impact of rapid molecular diagnostic testing of
respiratory viruses on outcomes of adults hospitalized with respiratory illness: a
multicenter quasi-experimental study. J Clin Microbiol 2019; 57:e01727-18.
9. Soto M, Sampietro-Colom L, Vilella A, et al. Economic impact of a new rapid
PCR assay for detecting influenza virus in an emergency department and hospitalized patients. PLoS One 2016; 11:e0146620.
10. Mahony JB, Blackhouse G, Babwah J, et al. Cost analysis of multiplex PCR testing
for diagnosing respiratory virus infections. J Clin Microbiol 2009; 47:2812–7.
11. Dundas NE, Ziadie MS, Revell PA, et al. A lean laboratory: operational simplicity
and cost effectiveness of the Luminex xTAG respiratory viral panel. J Mol Diagn
2011; 13:175–9.
12. Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of
viral and atypical bacterial pathogens by real-time polymerase chain reaction for
patients with lower respiratory tract infection. Clin Infect Dis 2005; 41:1438–44.
13. Schechter-Perkins EM, Mitchell PM, Nelson KP, et al. Point-of-care influenza
testing does not significantly shorten time to disposition among patients with an
influenza-like illness. Am J Emerg Med 2019; 37:873–8.
14. Wishaupt JO, Russcher A, Smeets LC, Versteegh FG, Hartwig NG. Clinical impact
of RT-PCR for pediatric acute respiratory infections: a controlled clinical trial.
Pediatrics 2011; 128:e1113–20.
15. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis
Making 1991; 11:88–94.
16. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the
Infectious Diseases Society of America: 2018 update on diagnosis, treatment,
chemoprophylaxis, and institutional outbreak management of seasonal influenza.
Clin Infect Dis 2019; 68:e1–47.
17. Centers for Disease Control and Prevention. Guide for considering influenza
testing when influenza viruses are circulating in the community. Available at:
https://www.cdc.gov/flu/professionals/diagnosis/consider-influenza-testing.htm.
Accessed 31 March 2020.

VIEWPOINTS • cid 2020:XX (XX XXXX) • 7

18. Centers for Disease Control and Prevention. Algorithm to assist in the interpretation of influenza testing results and clinical decision-making during periods
when influenza viruses are circulating in the community. Available at: https://
www.cdc.gov/flu/professionals/diagnosis/algorithm-results-circulating.htm.
Accessed 31 March 2020.
19. Dugas AF, Coleman S, Gaydos CA, Rothman RE, Frick KD. Cost-utility of rapid
polymerase chain reaction-based influenza testing for high-risk emergency department patients. Ann Emerg Med 2013; 62:80–8.
20. Lee BY, McGlone SM, Bailey RR, et al. To test or to treat? An analysis of influenza
testing and antiviral treatment strategies using economic computer modeling.
PLoS One 2010; 5:e11284.
21. Brendish NJ, Malachira AK, Beard KR, Ewings S, Clark TW. Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a post
hoc analysis from a randomised controlled trial. Eur Respir J 2018; 52:1800555.
22. Echavarría M, Marcone DN, Querci M, et al. Clinical impact of rapid molecular
detection of respiratory pathogens in patients with acute respiratory infection. J
Clin Virol 2018; 108:90–5.
23. Infectious Diseases Society of America. COVID-19 prioritization of diagnostic testing.
Available
at:
https://www.idsociety.org/news--publications-new/articles/2020/idsastatement-on-covid-19-testing-recommendations/. Accessed 6 April 2020.
24. Dignan FL, Clark A, Aitken C, et al; Haemato-oncology Task Force of the British
Committee for Standards in Haematology; British Society for Blood and Marrow
Transplantation and the UK Clinical Virology Network. BCSH/BSBMT/UK
clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. Br J Haematol 2016; 173:380–93.
25. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth
European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus,
metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56:258–66.
26. Manuel O, Estabrook M; American Society of Transplantation Infectious Diseases
Community of Practice. RNA respiratory viral infections in solid organ transplant
recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019; 33:e13511.
27. von Lilienfeld-Toal M, Berger A, Christopeit M, et al. Community acquired respiratory virus infections in cancer patients—guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for
Haematology and Medical Oncology. Eur J Cancer 2016; 67:200–12.
28. Ralston SL, Lieberthal AS, Meissner HC, et al; American Academy of Pediatrics.
Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134:e1474–502.
29. Semret M, Schiller I, Jardin BA, et al. Multiplex respiratory virus testing for antimicrobial stewardship: a prospective assessment of antimicrobial use and clinical
outcomes among hospitalized adults. J Infect Dis 2017; 216:936–44.
30. Green DA, Hitoaliaj L, Kotansky B, Campbell SM, Peaper DR. Clinical utility of
on-demand multiplex respiratory pathogen testing among adult outpatients. J
Clin Microbiol 2016; 54:2950–5.
31. Campbell AP, Guthrie KA, Englund JA, et al. Clinical outcomes associated with
respiratory virus detection before allogeneic hematopoietic stem cell transplant.
Clin Infect Dis 2015; 61:192–202.
32. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with
community-acquired pneumonia: an official clinical practice guideline of the
American Thoracic Society and Infectious Diseases Society of America. Am J
Respir Crit Care Med 2019; 200:e45–67.
33. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospitalacquired and ventilator-associated pneumonia: 2016 clinical practice guidelines
by the Infectious Diseases Society of America and the American Thoracic Society.
Clin Infect Dis 2016; 63:e61–111.
34. Faron ML, Mahmutoglu D, Huang A, et al. Clinical evaluation of a semiquantitative multiplex molecular assay for the identification of bacteria, viruses, and fungi in lower respiratory specimens. Clinical Virology Symposium;
Savannah, GA; 2017.
35. Vos LM, Bruning AHL, Reitsma JB, et al. Rapid molecular tests for influenza,
respiratory syncytial virus, and other respiratory viruses: a systematic review of
diagnostic accuracy and clinical impact studies. Clin Infect Dis 2019; 69:1243–53.
36. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382:1177–9.
37. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized
patients with COVID-2019. Nature 2020. doi:10.1038/s41586-020-2196-x.
38. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical
samples. Lancet Infect Dis 2020; 20:411–2.
39. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical
specimens. JAMA 2020. doi:10.1001/jama.2020.3786.
40. Winichakoon P, Chaiwarith R, Liwsrisakun C, et al. Negative nasopharyngeal and oropharyngeal swab does not rule out COVID-19. J Clin Microbiol 2020; 58:e00297-20.

8 • cid 2020:XX (XX XXXX) • VIEWPOINTS

41. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020.
doi:10.1148/radiol.2020200642.
42. Subramony A, Zachariah P, Krones A, Whittier S, Saiman L. Impact of multiplex polymerase chain reaction testing for respiratory pathogens on healthcare
resource utilization for pediatric inpatients. J Pediatr 2016; 173:196–201.e2.
43. Brendish NJ, Mills S, Ewings S, Clark TW. Impact of point-of-care testing for respiratory viruses on antibiotic use in adults with exacerbation of airways disease. J
Infect 2019; 79:357–62.
44. Richardson L, Brite J, Del Castillo M, et al. Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy. Clin Microbiol Infect 2016; 22:380, e1–7.
45. Jansen RR, Wieringa J, Koekkoek SM, et al. Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values. J Clin
Microbiol 2011; 49:2631–6.
46. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for
respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 2016;
62:817–23.
47. Lee SH, Ruan SY, Pan SC, Lee TF, Chien JY, Hsueh PR. Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and
the main determinants of resistance from the lower respiratory tract specimens of
adult patients in intensive care units. J Microbiol Immunol Infect 2019; 52:920–8.
48. Lee N, Chan PK, Wong CK, et al. Viral clearance and inflammatory response
patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16:237–47.
49. Piralla A, Pariani E, Rovida F, et al; Severe Influenza A Task Force. Segregation of
virulent influenza A(H1N1) variants in the lower respiratory tract of critically ill
patients during the 2010-2011 seasonal epidemic. PLoS One 2011; 6:e28332.
50. Yeh E, Luo RF, Dyner L, et al. Preferential lower respiratory tract infection in
swine-origin 2009 A(H1N1) influenza. Clin Infect Dis 2010; 50:391–4.
51. Englund JA, Piedra PA, Jewell A, Patel K, Baxter BB, Whimbey E. Rapid diagnosis
of respiratory syncytial virus infections in immunocompromised adults. J Clin
Microbiol 1996; 34:1649–53.
52. Gadsby NJ, McHugh MP, Forbes C, et al. Comparison of Unyvero P55 Pneumonia
Cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care
setting. Eur J Clin Microbiol Infect Dis 2019; 38:1171–8.
53. Ozongwu C, Personne Y, Platt G, et al. The Unyvero P55 “sample-in, answer-out” pneumonia assay: a performance evaluation. Biomol Detect Quantif 2017; 13:1–6.
54. Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment,
and prevention. Clin Microbiol Rev 2006; 19:637–57.
55. BioFire Diagnostics. Diagnostics B. FilmArray pneumonia panel instructions for
use. Available at: https://www.biofiredx.com/support/documents/. Accessed 19
February 2020.
56. Rand K, Beal S, Tremblay E, Houck H, Weber K, Sistrom C. Relationship of a
multiplex molecular pneumonia panel (PP) results with hospital outcomes and
clinical variables. Open Forum Infect Dis 2019; 6(Suppl 2): S299.
57. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship
program: guidelines by the Infectious Diseases Society of America and the Society
for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62:e51–77.
58. Branche AR, Walsh EE, Jadhav N, et al. Provider decisions to treat respiratory
illnesses with antibiotics: insights from a randomized controlled trial. PLoS One
2016; 11:e0152986.
59. Abbas S, Bernard S, Lee KB, et al. Rapid respiratory panel testing: Impact of active
antimicrobial stewardship. Am J Infect Control 2019; 47:224–5.
60. Mercuro NJ, Kenney RM, Samuel L, Tibbetts RJ, Alangaden GJ, Davis SL.
Stewardship opportunities in viral pneumonia: why not the immunocompromised? Transpl Infect Dis 2018; 20:e12854.
61. Srinivas P, Rivard KR, Pallotta AM, et al. Implementation of a stewardship initiative on respiratory viral PCR-based antibiotic deescalation. Pharmacotherapy
2019; 39:709–17.
62. Branche AR, Walsh EE, Vargas R, et al. Serum procalcitonin measurement and
viral testing to guide antibiotic use for respiratory infections in hospitalized
adults: a randomized controlled trial. J Infect Dis 2015; 212:1692–700.
63. Lydon EC, Henao R, Burke TW, et al. Validation of a host response test to
distinguish bacterial and viral respiratory infection. EBioMedicine 2019;
48:453–61.
64. Pulido MR, Moreno-Martinez P, Gonzalez-Galan V, et al. Application of BioFire
FilmArray Blood Culture Identification panel for rapid identification of the causative agents of ventilator-associated pneumonia. Clin Microbiol Infect 2018;
24:1213.e1–.e4.
65. Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The
effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis 2017; 64:15–23.

